PHIO News and Press, Phio Pharmaceuticals Corp. From 07/25/25

2025-07-25 08:24:30 ET More on Phio Pharmaceuticals Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financial information for Phio Pharmaceuticals Read the full article on Seeking Alpha For...

Agreement covers contract development and manufacturing of lead compound PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL &#...

-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohort Marlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmac...

- Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...

Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ET Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL...

2025-05-15 16:50:16 ET More on Phio Pharmaceuticals Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financial information for Phio Pharmaceuticals Read the full article on Seeking Alpha For...

Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical study Marlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical compan...

Replimune Group Inc. (REPL) is expected to report $-0.75 for Q4 2025 Adcore (ADCOF) is expected to report for Q1 2025 Equillium Inc. (EQ) is expected to report $-0.22 for Q1 2025 Credicorp Ltd. (BAP) is expected to report $5.31 for Q1 2025 Pelangio Exploration Inc (PGXPF) is expec...

2025-05-14 18:48:08 ET Phio Pharmaceuticals Corp. (PHIO) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.84%. The average open to low on the day of earnings was -6.17%. The average ope...

2025-05-14 18:43:07 ET Phio Pharmaceuticals Corp. (PHIO) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in PHIO stock price following earnings has averaged ±2.13% , with a median of 1.54...